Frost & Sullivan Research Service   Published: 22 Dec 2008
Drug Approval Process in Europe - An Outlook
   Research Overview

This Frost & Sullivan research service titled Drug Approval Process in Europe - An Outlook provides an insight into the mutual recognition procedure, centralised procedure, price controls, and parallel trading. In this research, Frost & Sullivan's expert analysts thoroughly examine the European Union (EU) regulatory processes, comparing the EU and the U.S.A.’s drug approval processes, price controls and parallel trading, biosimilars approval, and bi-lateral and tri-lateral integration.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.

Market Overview

Transatlantic Regulatory Integration of Drug Approval Process Fundamental for the Success of the Global Pharmaceutical Industry

The diverse regulatory environment across the EU and the United States needs to be integrated to overcome challenges during drug launches. Different regulations impact the drug launches as less-price controlled markets witness quicker launches, while it takes longer in regulated markets. The pharmaceutical industry along with the regulatory agencies has been working closely with the The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) to develop a standard set of regulatory process for Europe, the United States, and Japan. “The future of the pharmaceutical industry lies in the globalization of the drug approval processes,” notes the analyst of this research. “Pan-European integration and transatlantic coordination on the regulatory front is high on the agenda for Europe, Middle East and Africa (EMEA) and the Food & Drug Administration in the United States.” Several companies are venturing into manufacturing biosimilars, since biologics are on the verge of patent expiry. This has led to the formation of new regulatory pathways for biosimilar approvals in the EU. The EU has pioneered the creation of a regulatory pathway for biosimilars in Europe.

However, the gap between European regulatory authorities and national pricing authorities needs to be bridged. Although centralised procedures authorise the sale of drugs in all member states, pharmaceutical companies still have to file for price or reimbursement approvals. Some countries have distinct methods of drug price approvals and their processes are not always transparent, making it difficult for drug manufacturers to do business in Europe. “The unfavourable regulatory environment, varying price controls across member states, and parallel trading hinder the growth of the pharmaceutical industry in Europe,” explains the analyst. “Due to the varied price regulations across EU, research-intensive firms undertake R&D activities in less price controlled markets.”

EU-wide synchronisation will make the approval process faster, reducing delays in drug launches. Transatlantic co-ordination will also aid in streamlining regulatory costs. Transatlantic regulatory convergence will have immense benefits such as faster technology transfer, regulating approval of unsafe drugs, and patent law harmonisation. “EMEA should encourage frequent dialogues with patient and industry representatives to ensure a transparent approval process,” concludes the analyst. “Such interaction will also aid in redefining the clinical trial design and streamline the drug approval process.”

Frost & Sullivan Growth Partnership Services

Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.

Our growth solutions support the entire growth process:

TEAM Research is a program that furnishes clients with access to market research, competitive intelligence, financial benchmarking, and market strategies and analysis, and provides access to industry experts to aid in generating growth opportunities.

Growth Consulting Services unite clients with our industry experts to evaluate opportunities and develop customized strategies and business plans to drive top-line revenue and margin growth.

Growth Team Membership™ is a career-focused offering that was developed to address the unique challenges that senior executives face when implementing strategies to achieve aggressive corporate growth targets.

  Table Of Contents

   List of Figures

Chapter 3

  • Drug Approval Process: Top Industry Challenges (Europe), 2008

Chapter 4

  • Drug Approval Process: National Competent Authorities (Europe), 2008
  • Drug Approval Process: Comparing the Drug Approval Systems in Europe and the United States (Europe), 2008
  • Drug Approval Process: Comparing the Biotech Industries in Europe and the
    United States (Europe), 2008

Chapter 5

  • Drug Approval Process: Methods Used for Price Comparison (Europe), 2008
  • Drug Approval Process: List of Countries Based on Drug Pricing (Europe), 2008
  • Drug Approval Process: National Pharmaceutical Pricing Regulation (Europe), 2008

Chapter 8

  • Decision Support Database: Number of Biotech Companies (World), 1999-2006
  • Decision Support Database: Number of Biotechnology Patents Filed at/Granted by the European
  • Patent Office (EPO) (World), 1996-2000
  • Decision Support Database: Number of Biotech Patents granted by USA Patent and Trademark Office (World), 1996-2000
  • Decision Support Database: Government R&D Investment in Biotechnology in Million USD (World), 1999-2006
  • Decision Support Database: Private Investment in Biotechnology in Million USD (World), 1999-2006

  Further Information

Enquiries from:
Tel: +27 21 680 3260
Enquiries from:
Asia Pacific:
Tel: +65 68900999
Enquiries from:
Tel: +44 (0) 20 7343 8383
Enquiries from:
Tel: +972-9-9502888
Enquiries from:
Latin America:
Tel: +54 11 4777 1550
Enquiries from:
Middle East and North Africa:
Tel: +971.4.4331.893
Enquiries from:
North America:
Tel: +1.877.GO.FROST (463.7678)
Enquiries from:
South Asia:
Tel: +91 (0) 22 6160 6666
For a full list of our offices click here.